Indivior (INDV) Projected to Announce Earnings on Thursday

Key Points

• Indivior is expected to report Q3 2026 earnings before the market opens on October 29. Analysts forecast earnings of $1.06 per share and revenue of $329.35 million, compared with $5.75 EPS and $343 million in revenue in the previous quarter.
• The company announced a special dividend of $8.13 per share, payable November 6 to shareholders of record on October 30.
• Analyst sentiment remains broadly positive, with the stock carrying an average “Buy” rating and a consensus price target of $45.17 versus its recent price of $34.79.

Indivior (NASDAQ:INDV - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Indivior to post earnings of $1.06 per share and revenue of $329.35 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The company had revenue of $343.00 million during the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. On average, analysts expect Indivior to post $3.66 EPS for the current fiscal year and $3.83 EPS for the next fiscal year.

Indivior Stock Performance

NASDAQ:INDV opened at $34.79 on Thursday. Indivior has a 1 year low of $24.03 and a 1 year high of $42.81. The stock has a fifty day moving average price of $35.66 and a two-hundred day moving average price of $36.86. The stock has a market capitalization of $4.11 billion, a price-to-earnings ratio of 12.47 and a beta of 0.87.

Indivior Announces Dividend

The business also recently announced a special dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 30th will be issued a $8.13 dividend.

Insiders Place Their Bets

In other Indivior news, CAO Woodrow D. Anderson bought 1,500 shares of the company's stock in a transaction on Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the acquisition, the chief accounting officer owned 27,638 shares of the company's stock, valued at $986,400.22. The trade was a 5.74% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.74% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Craig Hallum reiterated a "buy" rating and set a $53.00 price target on shares of Indivior in a research report on Tuesday, August 4th. Weiss Ratings cut Indivior from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, September 24th. Barclays dropped their price objective on Indivior from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Wednesday, August 5th. Finally, Zacks Research raised Indivior from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $45.17.

About Indivior

Indivior PLC NASDAQ: INDV is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company's principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.